Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.
Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...
Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy Lymph node metastasis (LNM) ...
South San Francisco, California Tuesday, March 10, 2026, 17:00 Hrs [IST] ...
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostatTango will sponsor the clinical trial and ...
Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the ...
Researchers at Fred Hutch Cancer Center are testing whether a collaborative AI research platform can accelerate the pace of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results